GLP-1类药物,如Ozempic切除药物使用紊乱风险,在美国的一项大型研究中,2型糖尿病的退伍军人中,这种风险最高达25%。 GLP-1 drugs like Ozempic cut substance use disorder risks by up to 25% in veterans with type 2 diabetes, per a large U.S. study.

美国对2型糖尿病老兵的一项大型研究发现,GLP-1受体激动剂药物,如Ozempic和Wegovy, 与酒精、尼古丁、类阿片、可卡因和大麻等药物使用紊乱的发病风险较低有关,风险降低幅度高达25%。 A large U.S. study of veterans with type 2 diabetes found that GLP-1 receptor agonist drugs like Ozempic and Wegovy were linked to lower risks of developing substance use disorders, including alcohol, nicotine, opioids, cocaine, and cannabis, with up to a 25% reduction in risk. 对于已经上瘾的人来说,与这些药物有关的紧急访问、住院、吸毒过量和死亡大幅减少。 For those already addicted, the drugs were associated with significantly fewer emergency visits, hospitalizations, overdoses, and deaths. 研究者认为这些药物可能会影响大脑的奖励制度, 从而减少渴望, 尽管这些药物没有被批准接受戒毒治疗, 不应该取代行为疗法。 Researchers suggest the drugs may reduce cravings by affecting the brain’s reward system, though they are not approved for addiction treatment and should not replace behavioral therapies.